18 results
8-K
EX-99.1
PNT
POINT Biopharma Global Inc.
14 Aug 23
POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
7:21am
line data is expected in the fourth quarter of 2023. Six trial sites remain open for recruitment to complete a separate pharmacokinetic sub-study
ARS
2022 FY
PNT
POINT Biopharma Global Inc.
1 May 23
Annual report to shareholders
1:52pm
2021. CTAs were also filed and are active in four other countries. Clinical Development and Next Steps POINT initiated participant recruitment for our … to interrupt, delay, or halt clinical trials. Treatment-related undesirable side effects or adverse events could also affect participant recruitment
424B3
pkcpx
31 Mar 22
Prospectus supplement
11:42am
POS AM
eab83e9gi6m30zkk6zk
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
nnqrt35 jka8dru5sf0z
5 Aug 21
Prospectus supplement
4:26pm
424B3
ylxmx
9 Jun 21
Prospectus supplement
4:42pm
S-4/A
EX-10.18
jocj4c
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
0gmb9z9bd5m oawc
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4
hd1l7s
22 Mar 21
Registration of securities issued in business combination transactions
9:52pm
S-4
EX-10.18
h86ouo6l vb
22 Mar 21
Registration of securities issued in business combination transactions
9:52pm
- Prev
- 1
- Next